Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,393 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hereditary Conditions Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Investigating the Relationship Between Triglycerides and Fetal Overgrowth in Gestational Diabetes

NCT06067685
View directory record Official record
Conditions
Fetal Macrosomia, Obesity Complicating Childbirth, Gestational Diabetes
Interventions
Observation
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 8, 2026, 5:29 PM EDT
Completed Not applicable Interventional

Macronutrient Regulation of Ghrelin and Peptide YY

NCT02464514
View directory record Official record
Conditions
Obesity, Prader Willi Syndrome
Interventions
High carbohydrate meal, High fat meal
Other
Lead sponsor
Duke University
Other
Eligibility
5 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 8, 2026, 5:29 PM EDT
Completed No phase listed Observational

Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)

NCT01810458
View directory record Official record
Conditions
Liver Fibrosis, Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD
Interventions
Abdominal ultrasound, History and physical, Intravenous catheter, Blood draw, Liver questionnaire, Liver Biopsy, Midazolam, Fentanyl, Lidocaine, Acetaminophen, Lorazepam, Oxycodone/Acetaminophen, Ondansetron
Device · Procedure · Other + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 8, 2026, 5:29 PM EDT
Completed Phase 1 Interventional

A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease

NCT01485965
View directory record Official record
Conditions
Huntington's Disease
Interventions
SEN0014196
Drug
Lead sponsor
Siena Biotech S.p.A.
Industry
Eligibility
25 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 8, 2026, 5:29 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Impact of Early Implementation of Narrative Medicine Techniques on Patient Centered Attitudes of Medical Students

NCT03041571
View directory record Official record
Conditions
Narrative Medicine, Chronic Disease, Terminal Illness, Cancer, Diabetes Mellitus, Cystic Fibrosis, Rheumatologic Disorder, Oncologic Disorders, Hematologic Diseases
Interventions
Patient Provider Orientation Scale, Interview performed by MHP student
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 8, 2026, 5:29 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

NCT04154033
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Dermatitis
Interventions
Naltrexone, Placebo Cream
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 8, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional

Codeine in Sickle Cell Disease

NCT00174538
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Codeine (30 mg)
Drug
Lead sponsor
PriCara, Unit of Ortho-McNeil, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 8, 2026, 5:29 PM EDT
Completed Phase 2 Interventional

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00003116
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, busulfan, cyclophosphamide, cyclosporine, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
4 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 8, 2026, 5:29 PM EDT
Completed No phase listed Observational

Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model

NCT03934606
View directory record Official record
Conditions
Pancreas Cancer, Prostate Cancer, Hereditary Cancer, Genetic Predisposition to Disease
Interventions
Genetic testing for hereditary predisposition
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
1,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 8, 2026, 5:29 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Intramuscular Uricase-PEG 20

NCT01038947
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Uricase-PEG 20
Biological
Lead sponsor
EnzymeRx
Industry
Eligibility
40 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2009 · Synced Oct 8, 2026, 5:29 PM EDT
Terminated Not applicable Interventional Results available

Feasibility of EnChroma Use in the Emergency Department Setting

NCT04021914
View directory record Official record
Conditions
Color Vision Defects
Interventions
EnChroma glasses
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 8, 2026, 5:29 PM EDT
No Longer Available No phase listed Expanded access

A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)

NCT06069934
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine
Drug
Lead sponsor
Prilenia
Industry
Eligibility
18 Years and older
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 8, 2026, 5:29 PM EDT
Completed Phase 1 Interventional

Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

NCT00087204
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
becatecarin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 8, 2026, 5:29 PM EDT
Completed Phase 4 Interventional Results available

Dexmedetomidine and Propofol for Pediatric MRI Sedation

NCT03513757
View directory record Official record
Conditions
Headache, Tumor, Seizure Disorder, Neurofibromatoses, Hydrocephalus, Abdominal Neoplasm, Spine Deformity
Interventions
propofol, Dexmedetomidine, Glycopyrrolate, Lidocaine 1% Injectable Solution, Nitrous Oxide, Sevoflurane
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Months to 60 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 8, 2026, 5:29 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

NCT00490100
View directory record Official record
Conditions
Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
Interventions
Increlex
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 20 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2015 · Synced Oct 8, 2026, 5:29 PM EDT
Terminated Phase 4 Interventional Results available

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

NCT05696392
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ruxolitinib cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
30
States / cities
Fountain Valley, California • Long Beach, California • Washington D.C., District of Columbia + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 8, 2026, 5:29 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Craniofacial Anomalies and Developmental Growth Variants

NCT02639312
View directory record Official record
Conditions
Prognathism, Retrognathism, Dentofacial Deformities
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
2 Years to 100 Years
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2046
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 8, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multiple Gestation Study

NCT02278536
View directory record Official record
Conditions
Trisomy 13, Trisomy 18, Trisomy 21, Sex Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
6
States / cities
San Carlos, California • San Diego, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 8, 2026, 5:29 PM EDT
Recruiting Not applicable Interventional

Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

NCT07521930
View directory record Official record
Conditions
Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS), Muscular Disorders, Atrophic, Brain Stem Stroke, Spinal Cord Injuries (SCI), Muscular Dystrophies, Muscular Atrophy, Progressive, Pontine Hemorrhage, Pontine Infarction
Interventions
INTENT Neural Interface System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 8, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional Results available

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

NCT01116232
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, rituximab, sirolimus, tacrolimus, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 8, 2026, 5:29 PM EDT
Recruiting Not applicable Interventional

Vancomycin Reduction Practices (VRP) in the NICU

NCT06772675
View directory record Official record
Conditions
Antibiotic Stewardship, Neonatal Sepsis, Late-Onset, Vancomycin
Interventions
External Facilitation
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Modesto, California • Oakland, California • Roseville, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 8, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care

NCT00023192
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
T-Cell Depleted & CD34+Select/w/StemCell Enriched Product
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 8, 2026, 5:29 PM EDT
Completed No phase listed Observational

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06064656
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Non-Interventional
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 8, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Fetal Alcohol Syndrome: Socio-Cognitive Habilitation

NCT00164229
View directory record Official record
Conditions
Fetal Alcohol Syndrome
Interventions
math, behavior regulation
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
42 Months to 81 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2008 · Synced Oct 8, 2026, 5:29 PM EDT